• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Neil S. Horowitz, MD


  • Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK.
    NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
    Cancer. 2015 Apr 6.
  • Aviki EM, Esselen KM, Barcia SM, Nucci MR, Horowitz NS, Feltmate CM, Berkowitz RS, Orgill DG, Viswanathan AN, Muto MG.
    Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva?.
    Gynecol Oncol. 2015 Apr;137(1):60-5.
  • Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL.
    Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analysis of GOG 182.
    J Clin Oncol. 2015 Mar 10;33(8):937-43.
  • Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A.
    Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
    Cell. 2015 Feb 26;160(5):977-89.
  • Maestá I, Horowitz NS, Goldstein DP, Bernstein MR, Ramírez LA, Moulder J, Berkowitz RS.
    Response to Chemotherapy in Overweight/Obese Patients With Low-Risk Gestational Trophoblastic Neoplasia.
    Int J Gynecol Cancer. 2015 Feb 11.
  • Rauh-Hain JA, Goodman A, Boruta DM, Schorge JO, Horowitz NS, del Carmen MG.
    Endometrial stromal sarcoma: a clinicopathologic study of 29 patients.
    J Reprod Med.;59(11-12):547-52.
  • Owusu-Darko S, Rauh-Hain JA, Horowitz NS, Goodman A, Schorge JO, Del Carmen MG.
    Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy.
    J Reprod Med.;59(11-12):527-33.
  • Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM.
    Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: A SEER analysis.
    Gynecol Oncol. 2014 May;133(2):216-20.
  • Worley MJ, Guseh SH, Rauh-Hain JA, Esselen KM, Muto MG, Feltmate CM, Berkowitz RS, Del Carmen MG, Schorge JO, Horowitz NS.
    What is the optimal treatment for obese patients with advanced ovarian carcinoma?.
    Am J Obstet Gynecol. 2014 Apr 1.
  • Viswanathan AN, Lee H, Berkowitz R, Berlin S, Campos S, Feltmate C, Horowitz N, Muto M, Sadow CA, Matulonis U.
    A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer.
    Gynecol Oncol. 2014 Jan;132(1):55-60.
  • Mitchell DG, Javitt MC, Glanc P, Bennett GL, Brown DL, Dubinsky T, Harisinghani MG, Harris RD, Horowitz NS, Pandharipande PV, Pannu HK, Podrasky AE, Royal HD, Shipp TD, Siegel CL, Simpson L, Wong-You-Cheong JJ, Zelop CM.
    ACR appropriateness criteria staging and follow-up of ovarian cancer.
    J Am Coll Radiol. 2013 Nov;10(11):822-7.
  • Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS.
    Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.
    Int J Gynecol Cancer. 2013 Sep;23(7):1219-25.
  • Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, Maxwell GL, Horowitz NS, Krivak TC.
    Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182.
    Gynecol Oncol. 2013 Sep;130(3):487-92.
  • Rauh-Hain JA, Shoni M, Schorge JO, Goodman A, Horowitz NS, del Carmen MG.
    Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
    J Reprod Med.;58(7-8):297-304.
  • Maestá I, Growdon WB, Goldstein DP, Bernstein MR, Horowitz NS, Rudge MV, Berkowitz RS.
    Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.
    Gynecol Oncol. 2013 Aug;130(2):312-6.
  • Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS.
    Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?.
    Gynecol Oncol. 2013 Apr;129(1):69-73.
  • Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, Del Carmen MG, Horowitz NS.
    Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Gynecol Oncol. 2013 Apr;129(1):63-8.
  • Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S.
    A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
    Gynecol Oncol. 2012 Aug 9.
  • Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS.
    Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2012 Jun 26.
  • Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S.
    Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Gynecol Oncol. 2012 May 30.
  • Quick CM, May T, Horowitz NS, Nucci MR.
    Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion.
    Int J Gynecol Pathol. 2012 Jul;31(4):337-43.
  • Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG.
    Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Gynecol Oncol. 2012 Feb 21.
  • Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS.
    Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
    Gynecol Oncol. 2012 Jan;124(1):53-8.
  • Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, Del Carmen MG, Schorge JO.
    Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer.
    Ann Surg Oncol. 2011 Oct 13.
  • Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK.
    Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
    Clinical Ovarian Cancer And Other Gynecologic Malignancies. 2011 Jun;4(1):26-33.
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.
    Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
    J Clin Oncol. 2010 Jan 1;28(1):154-9.
  • Horowitz NS,Goldstein DP,Berkowitz RS.
    Management of gestational trophoblastic neoplasia.
    Semin Oncol. 2009 Apr;36(2):181-9. Review.
  • Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT.
    Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors.
    Gynecol Oncol. 2009 Feb;112(2):394-9.
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT.
    Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    J Clin Oncol. 2008 Dec 10;26(35):5761-6.
  • Growdon WB,Boisvert SL,Akhavanfard S,Oliva E,Dias-Santagata DC,Kojiro S,Horowitz NS,Iafrate AJ,Borger DR,Rueda BR.
    Decreased survival in EGFR gene amplified vulvar carcinoma.
    Gynecol Oncol. 2008 Nov;111(2):289-97.
  • Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI, Oliva E.
    Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
    N Engl J Med. 2006 Apr 13;354(15):1615-25.
  • Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG.
    Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer.
    Gynecol Oncol. 2004 Dec;95(3):546-51.